Cinacalcet Dosing for Hyperparathyroidism
For secondary hyperparathyroidism in CKD stage 5D (dialysis), start cinacalcet at 30 mg once daily and titrate up to 180 mg once daily to achieve target PTH levels; for primary hyperparathyroidism in non-surgical candidates, use the same starting dose of 30 mg once daily with titration based on serum calcium normalization. 1, 2
Secondary Hyperparathyroidism in CKD Stage 5D (Dialysis)
Starting Dose and Titration
- Begin with 30 mg once daily orally 1
- Titrate in increments every 2-4 weeks up to a maximum of 180 mg once daily to achieve target intact PTH ≤250-300 pg/mL 1
- This dosing regimen applies equally to both hemodialysis and peritoneal dialysis patients, with 50% of PD patients achieving mean iPTH ≤300 pg/mL 1
Expected Outcomes
- Approximately 46% of patients achieve mean iPTH ≤300 pg/mL, and 65% achieve ≥30% reduction in iPTH from baseline 1
- The medication reduces serum PTH by a mean of 281 ng/L and serum calcium by 0.22 mmol/L 3, 4
- Treating 1,000 patients for 1 year prevents approximately 3 parathyroidectomies (RR 0.49) but causes around 60 cases of hypocalcemia and 150 cases of nausea 3, 4
Important Limitations
- Cinacalcet has little or no effect on all-cause mortality (RR 0.97) and should primarily be considered only for preventing parathyroidectomy in patients where surgery is contraindicated 3, 4
- Current evidence does not support routine use of calcimimetics to decrease serum PTH levels in CKD patients on dialysis 3
Primary Hyperparathyroidism (Non-Surgical Candidates)
Starting Dose and Titration
- Start with 30 mg once daily 2, 5
- Titrate upward until serum calcium normalizes or side effects prevent further increases 2, 5
- Maintenance doses typically range from 30 mg once daily to 60 mg twice daily (median 30 mg twice daily) 5
Expected Outcomes
- 94% of patients achieve normal total serum calcium, and 81% achieve normal ionized calcium 2
- PTH reduction is modest—only 25% achieve normal PTH levels despite calcium normalization 2
- Mean serum calcium decreases from approximately 12.2 mg/dL to 9.9 mg/dL 5
CKD Stages 3-4 (Not on Dialysis)
Dosing for Moderate CKD
- Start with 30 mg once daily and titrate up to 180 mg once daily to achieve ≥30% reduction in iPTH 6
- This applies to patients with eGFR 15-50 mL/min/1.73 m² and iPTH >130 pg/mL 6
- 56% of patients achieve ≥30% reduction in iPTH levels, with mean iPTH decreasing by 32% 6
- Serum calcium and phosphorus remain within normal range throughout treatment 6
Severe Renal Impairment Considerations
- No specific dose adjustment is explicitly required for eGFR <30 mL/min/1.73 m², but use the same starting dose of 30 mg once daily with careful monitoring 6
- A slight reduction in renal function (increased serum creatinine) may occur at months 2-3 of treatment 7
Monitoring and Safety
Common Adverse Effects
- Hypocalcemia risk increases 7.38-fold—monitor serum calcium closely 3, 4
- Gastrointestinal effects are most common: nausea (RR 2.05), vomiting (RR 1.95), and diarrhea (RR 1.15) 3, 4
- These GI symptoms are typically mild to moderate and transient 1
Critical Monitoring Parameters
- Monitor serum calcium, phosphorus, and PTH levels regularly during titration 1
- Target serum calcium levels should remain within normal range (approximately 8.5-10.5 mg/dL) 2, 5
- For secondary hyperparathyroidism, target iPTH ≤250-300 pg/mL 1
Key Clinical Pitfalls
- Do not use cinacalcet routinely in all CKD patients with elevated PTH—reserve for specific indications such as preventing parathyroidectomy when surgery is contraindicated 3
- Cinacalcet normalizes calcium but only modestly reduces PTH in primary hyperparathyroidism—do not expect complete PTH normalization 2
- Use with extreme caution in X-linked hypophosphatemia due to severe hypocalcemia risk and QT prolongation 8
- Evidence is primarily limited to CKD stage 5D patients; data for peritoneal dialysis patients are less robust 3
- Adverse events occur in approximately 43% of patients and may require treatment withdrawal in some cases 5